

Congress of the United States
Washington, DC 20515

August 31, 2018

The Honorable Jefferson Sessions
Attorney General
U.S. Department of Justice (DOJ)
950 Pennsylvania Avenue, NW
Washington, DC 20530-0001

Dear Attorney General Sessions:

In light of the fact that August 11, 2018 marked two years since the Drug Enforcement Administration (DEA) stated that they would accept registrations for manufacturers of marijuana for research usage, we write to encourage you to finalize your review of the submitted applications.

As we expressed to you nearly four months ago, in our letter dated April 30, 2018, compliant manufacturers are attempting to provide state and federal governments and medical professionals with rigorous research on cannabis' effects, both adverse and therapeutic, but their applications to do so have not been assessed. Our nation needs scientific research to analyze the medical applications of cannabis so we may determine appropriate federal marijuana policy in accordance with federal law. It is good policy, it is simply the right thing to do, and it falls within our national controlled substances regulatory framework.

As a bipartisan group of Members of Congress, we feel obliged to make clear our position on marijuana research:

1. The production of marijuana for compliant research should be apolitical.
2. Lawmakers, regulators, law enforcement officials and patients must be able to draw from a robust body of scientific research to make informed decisions about marijuana usage.
3. The need for expanded marijuana research in the United States is critical and urgent.

To prevent further delays in approving pending DEA applications for licenses to manufacture marijuana for research purposes, we ask you to respond to the following questions at your earliest convenience:


1. What is the current status of the twenty-six marijuana manufacturer applications?
2. In the past twelve months, excluding Schedule I Bulk Manufacturer registrations for marijuana, how many new DEA registrations has DOJ reviewed?
3. What steps have both the DEA and DOJ taken to review the twenty-six marijuana manufacturer applications currently pending?
4. By what date do you estimate the DEA will have completed its review of the twenty-six marijuana applications and commence registration of new marijuana manufacturers?

We look forward to your department addressing these questions and swiftly registering additional producers of marijuana for research. Thank you for your attention to this matter.


Sincerely,



Carlos Curbelo
Member of Congress



Jimmy Panetta
Member of Congress



Matt Gaetz
Member of Congress




Earl Blumenauer
Member of Congress



Dana Rohrabacher
Member of Congress



Steve Cohen
Member of Congress



Don Young
Member of Congress



Charlie Crist
Member of Congress



Tom Garrett
Member of Congress




Eleanor Holmes Norton
Member of Congress




Ryan Costello
Member of Congress



Anna G. Eshoo
Member of Congress



Zoe Lofgren
Member of Congress

A handwritten signature in blue ink, appearing to read "Jared Polis". The signature is stylized with large loops and a dot at the end of the last letter.

Jared Polis
Member of Congress